Drug Trial Radar · NCT00144417
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
Last checked: Nov 19, 2026Latest source record: Aug 3, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
433
Actual
Start
Feb 2006
Primary completion
Jun 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Global Alliance for TB Drug Development; Bayer
- First posted
- Sep 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.
Conditions
- Tuberculosis
Interventions
Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)Drug
Moxifloxacin 400mg daily, 8 weeks
isoniazidDrug
isoniazid, oral, 300 mg, daily, 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- • To compare the culture-conversion rate at the end of the intensive phase of therapy of the moxifloxacin regimen vs. that of the isoniazid regimenTime frame: 8 weeks
Locations
26 sites in 6 countries. Site status is shown where the registry gives one.
Veterans Administration Medical Center of Arkansas
Little Rock, Arkansas
University of Southern California Medical Center
Los Angeles, California
University of California at San Diego
San Diego, California
University of California, San Francincisco
San Francisco, California
Denver Public Health Department
Denver, Colorado
Washington DC Veterans Administration Medical Center
Washington D.C., District of Columbia
Emory University School of Medicine
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Hines Veterans Administration Medical Center
Hines, Illinois
Johns Hopkins University School of Medicine
Baltimore, Maryland
Boston University Medical Center
Boston, Massachusetts
New Jersey School of Medicine
Newark, New Jersey
Columbia University
New York, New York
Harlem Hospital, Columbia University
New York, New York
Duke University Medical Center
Durham, North Carolina
Veterans Administration Tennessee Valley Health Care System
Nashville, Tennessee
University of North Texas Health Science Center
Fort Worth, Texas
Houston Veterans Administration Medical Center
Houston, Texas
Audie L Murphy Memorial Veterans Administration Medical Center
San Antonio, Texas
Seattle-King County Health Department
Seattle, Washington
Hopital Universitario Clementino Fraga Filho
Rio de Janeiro, Rio de Janeiro, Brazil
University of Manitoba
Winnepeg, Manitoba, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Nelson R. Mandela School of Medicine
Durban, KwaZulu-Natal, South Africa
Agencia de Salut Publica
Barcelona, Spain
Makerere University Medical School
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.